Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016 (2016), Article ID 9406319, 8 pages
http://dx.doi.org/10.1155/2016/9406319
Review Article

CEACAM1: Expression and Role in Melanocyte Transformation

1Colentina Clinical Hospital, 1st Dermatology Department, “Carol Davila” University of Medicine and Pharmacy, 020125 Bucharest, Romania
2Department of Pathophysiology II, Clinical Department No. 2, “Carol Davila” University of Medicine and Pharmacy, 021105 Bucharest, Romania
3Pathology Department, Colentina Clinical Hospital, “Carol Davila” University of Medicine and Pharmacy, 020125 Bucharest, Romania
4Department of Medicine, Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 208028, USA

Received 8 April 2016; Revised 7 July 2016; Accepted 25 July 2016

Academic Editor: Simone Ribero

Copyright © 2016 Gabriela Turcu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Metastases represent the main cause of death in melanoma patients. Despite the current optimized targeted therapy or immune checkpoint inhibitors the treatment of metastatic melanoma is unsatisfactory. Because of the poor prognosis of advanced melanoma there is an urgent need to identify new biomarkers to differentiate melanoma cells from normal melanocytes, to stratify patients according to their risk, and to identify subgroups of patients that require close follow-up or more aggressive therapy. Furthermore, melanoma progression has been associated with the dysregulation of cell adhesion molecules. We have reviewed the literature and have discussed the important role of the expression of the carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) in the development of melanoma. Thus, novel insights into CEACAM1 may lead to promising strategies in melanoma treatment, in monitoring melanoma patients, in assessing the response to immunotherapy, and in completing the standard immunohistochemical panel used in melanoma examination.